Outcomes of hemodiafiltration based on Japanese dialysis patient registry

Shigeru Nakai, Kunitoshi Iseki, Kaoru Tabei, Kazuo Kubo, Ikuto Masakane, Kiyohide Fushimi, Kenjiro Kikuchi, Toru Shinzato, Tsutomu Sanaka, Takashi Akiba

研究成果: Article査読

59 被引用数 (Scopus)


Effectiveness of various therapeutic modalities was analyzed among 1, 196 patients entered in the registry of the Japanese Society for Dialysis Therapy who were on hemopurification therapy as of the end of 1998 and developed dialysis-related amyloidosis during 1999. In the investigation, the effectiveness of various hemopurification modalities on the dialysis-related amyloidosis was ranked as exacerbation, unchanged, or alleviation, so as to analyze the possible relationship between the hemopurification modality and its effectiveness. The analysis was performed using a logistic regression approach, and the results were shown as "the risk of a worse therapeutic ranking" among the hemopurification modalities. The smaller "the risk of a worse therapeutic effect" was, the more effective the treatment modality. When the risk of a worse therapeutic effect for the hemodialysis patients treated by a regular membrane was put at 1.0, the risk for hemodialysis patients using high-flux membrane was 0.489, the off-line hemodiafiltration risk was 0.117, the on-line hemodiafiltration risk was 0.013, and the risk of push/pull hemodiafiltration was 0.017. For hemodialysis with a β2-microglobulin adsorption column, a low risk of 0.054 was found. The results indicated that hemodiafiltration therapy and simultaneous hemodialysis with β2-microglobulin adsorption therapy were more effective treatment for dialysis-related amyloidosis.

ジャーナルAmerican Journal of Kidney Diseases
出版ステータスPublished - 10-2001

All Science Journal Classification (ASJC) codes

  • 腎臓病学


「Outcomes of hemodiafiltration based on Japanese dialysis patient registry」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。